CDSCO, Himachal Drug Authority bust fake drug racket in Paonta Sahib

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-07-08 09:00 GMT | Update On 2025-07-08 09:00 GMT

CDSCO, Himachal Drug Authority raid

Solan: In a major crackdown on the illegal pharmaceutical trade, a joint team of the Central Drugs Standard Control Organisation (CDSCO) and the Himachal Pradesh Drug Control Administration has uncovered a racket involved in the supply of counterfeit Active Pharmaceutical Ingredients (APIs) in the Sirmaur district.

The surprise raid—sparked by a tip-off—targeted a licensed wholesale drug premises near Paonta Sahib bus stand. Two APIs — Thiocolchicoside and Azithromycin, suspected to be fake, were recovered from the site.

Drug Controller Dr. Manish Kapoor said the fake APIs included Encrythiocolchicoside, used for muscle spasms, and Azithromycin, a common antibiotic. The owner failed to provide any purchase records and has been detained.

Preliminary probe revealed the fake materials were being supplied from Uttarakhand, where two more arrests have been made. The investigation is ongoing, and further action is likely.

As per UNI report, Dr. Kapoor warned that such crimes are serious threats to public health and strict action would be taken under the Drugs and Cosmetics Act, 1940. He added that drug inspectors have been told to speed up the investigation and take legal action.

In a related development, the CDSCO bulletin for February 2025 flagged 38 drug samples from Himachal Pradesh as “Not of Standard Quality.” Many of these failed medicines were traced to units operating in the Solan district, particularly Baddi, Barotiwala and Nalagarh.

Following this, the Solan district administration and the State Drug Authority conducted joint raids and seized defective drug batches. These included injections containing particles and common tablets like Calcium-Vitamin D3, Amoxyheal-CV, Para 500, Rabicy-20, and Diclowin Plus.

State officials said batch recalls have been initiated and show-cause notices have been sent to the companies involved. The Drug Controller said Himachal Pradesh has zero tolerance for spurious or substandard drugs and will continue strict surveillance.

The government is also working on setting up a new state-of-the-art drug testing laboratory in Baddi to ensure better quality checks in future.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO, Himachal Drug Authority bust fake drug racket in Paonta Sahib

Similar News

GSK, Hengrui Pharma to develop up to 12 medicines across Respiratory, Immunology & Inflammation and Oncology

AstraZeneca Imfinzi gets USFDA priority review for resectable early stage gastric, gastroesophageal junction cancers

Bristol Myers Squibb, Bain Capital form new biopharmaceutical company - NewCo

Bayer Sevabertinib accepted for review in China for advanced non-small cell lung cancer

Boehringer Ingelheim, Re-Vana Therapeutics ink pact to develop extended release therapies for eye diseases

Roche Slammed for Seeking Zydus' Confidential Process for Cancer Drug Sigrima Without Meeting Patent Threshold

Ranitidine Under Cancer Cloud: CDSCO Calls for Monitoring NDMA Levels, Shelf Life Cuts

E-Pharmacy Threat Growing Unchecked: AIOCD Flags Regulatory Failure, Calls for Urgent CDSCO Action